Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27


Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Maurer B, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Sowell CG, Wang X, Wong H, Xiong JM, Xu J, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7. doi: 10.1016/j.bmcl.2015.01.032. Epub 2015 Feb 7.


Targeting IgE production in mice and humans.

Wu LC, Scheerens H.

Curr Opin Immunol. 2014 Dec;31:8-15. doi: 10.1016/j.coi.2014.08.001. Epub 2014 Aug 25.


Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM.

Sci Transl Med. 2014 Jul 2;6(243):243ra85. doi: 10.1126/scitranslmed.3008961.


Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.


OX40L blockade and allergen-induced airway responses in subjects with mild asthma.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M, Kipling C, Dua B, Mosesova S, Putnam W, Zheng Y, Scheerens H, McClintock D, Matthews JG, O'Byrne PM.

Clin Exp Allergy. 2014 Jan;44(1):29-37. doi: 10.1111/cea.12235.


The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.


Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Spiess C, Bevers J 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, Scheer JM, Giese G, Persson J, Zhang Y, Dennis MS, Giulianotti J, Gupta P, Reilly D, Palma E, Wang J, Stefanich E, Scheerens H, Fuh G, Wu LC.

J Biol Chem. 2013 Sep 13;288(37):26583-93. doi: 10.1074/jbc.M113.480483. Epub 2013 Jul 23.


Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.


Redefining approaches to asthma: developing targeted biologic therapies.

Arron JR, Scheerens H, Matthews JG.

Adv Pharmacol. 2013;66:1-49. doi: 10.1016/B978-0-12-404717-4.00001-9. Review.


MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.

Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, Chindalore V, Bingham CO 3rd, Davis JC Jr.

Arthritis Res Ther. 2011;13(5):R177. doi: 10.1186/ar3502. Epub 2011 Oct 26.


Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.


Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Zheng Y, Scheerens H, Davis JC Jr, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG.

Clin Pharmacol Ther. 2011 Feb;89(2):283-90. doi: 10.1038/clpt.2010.311. Epub 2010 Dec 29.


Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT.

ChemMedChem. 2007 Jan;2(1):58-61. No abstract available.


Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.

Sperandio D, Tai VW, Lohman J, Hirschbein B, Mendonca R, Lee CS, Spencer JR, Janc J, Nguyen M, Beltman J, Sprengeler P, Scheerens H, Lin T, Liu L, Gadre A, Kellogg A, Green MJ, McGrath ME.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4085-9. Epub 2006 May 24.


IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D.

J Clin Invest. 2006 May;116(5):1310-6.


Accelerated alveolar bone loss in mice lacking interleukin-10: late onset.

Al-Rasheed A, Scheerens H, Srivastava AK, Rennick DM, Tatakis DN.

J Periodontal Res. 2004 Jun;39(3):194-8.


Role of NADPH oxidase-derived superoxide in reduced size liver ischemia and reperfusion injury.

Harada H, Hines IN, Flores S, Gao B, McCord J, Scheerens H, Grisham MB.

Arch Biochem Biophys. 2004 Mar 1;423(1):103-8.


Accelerated alveolar bone loss in mice lacking interleukin-10.

Al-Rasheed A, Scheerens H, Rennick DM, Fletcher HM, Tatakis DN.

J Dent Res. 2003 Aug;82(8):632-5.


Regulation of postischemic liver injury following different durations of ischemia.

Hines IN, Hoffman JM, Scheerens H, Day BJ, Harada H, Pavlick KP, Bharwani S, Wolf R, Gao B, Flores S, McCord JM, Grisham MB.

Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G536-45. Epub 2002 Nov 20.


Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Körner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD.

Immunity. 2001 Oct;15(4):533-43.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk